---
document_datetime: 2023-09-21 17:30:54
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/naglazyme-epar-all-authorised-presentations_en.pdf
document_name: naglazyme-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8104115
conversion_datetime: 2025-12-28 00:41:01.245645
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU Number       | Invented name   | Strength   | Pharmaceutical Form                   | Route of        | Packaging    | Content       | Package size   |
|-----------------|-----------------|------------|---------------------------------------|-----------------|--------------|---------------|----------------|
|                 |                 |            |                                       | Administration  |              |               |                |
| EU/1/05/324/001 | Naglazyme       | 1 mg/ml    | Concentrate for solution for infusion | Intravenous use | vial (glass) | 5 ml (1mg/ml) | 1 vial         |
| EU/1/05/324/002 | Naglazyme       | 1 mg/ml    | Concentrate for solution for infusion | Intravenous use | vial (glass) | 5 ml (1mg/ml) | 6 vial         |